These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

812 related items for PubMed ID: 11463009

  • 1. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.
    Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB, Bartels CC, Verhoog LC, van den Ouweland AM, Niermeijer MF, Brekelmans CT, Klijn JG.
    N Engl J Med; 2001 Jul 19; 345(3):159-64. PubMed ID: 11463009
    [Abstract] [Full Text] [Related]

  • 2. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
    Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, Olopade OI, Weber BL, Prevention and Observation of Surgical End Points Study Group.
    N Engl J Med; 2002 May 23; 346(21):1616-22. PubMed ID: 12023993
    [Abstract] [Full Text] [Related]

  • 3. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
    Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van 't Veer L, Garber JE, Evans GR, Narod SA, Isaacs C, Matloff E, Daly MB, Olopade OI, Weber BL.
    J Clin Oncol; 2004 Mar 15; 22(6):1055-62. PubMed ID: 14981104
    [Abstract] [Full Text] [Related]

  • 4. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
    Meijers-Heijboer H, Brekelmans CT, Menke-Pluymers M, Seynaeve C, Baalbergen A, Burger C, Crepin E, van den Ouweland AW, van Geel B, Klijn JG.
    J Clin Oncol; 2003 May 01; 21(9):1675-81. PubMed ID: 12721241
    [Abstract] [Full Text] [Related]

  • 5. Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations.
    Schrag D, Kuntz KM, Garber JE, Weeks JC.
    N Engl J Med; 1997 May 15; 336(20):1465-71. PubMed ID: 9148160
    [Abstract] [Full Text] [Related]

  • 6. Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer.
    Kaas R, Verhoef S, Wesseling J, Rookus MA, Oldenburg HS, Peeters MJ, Rutgers EJ.
    Ann Surg; 2010 Mar 15; 251(3):488-92. PubMed ID: 20134318
    [Abstract] [Full Text] [Related]

  • 7. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A, Peterson SK, Erlichman J, Broglio K, Yekell S, Schmeler K, Lu K, Meric-Bernstam F, Amos C, Strong L, Arun B.
    Cancer; 2006 Dec 15; 107(12):2745-51. PubMed ID: 17109443
    [Abstract] [Full Text] [Related]

  • 8. Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis.
    Grann VR, Jacobson JS, Whang W, Hershman D, Heitjan DF, Antman KH, Neugut AI.
    Cancer J Sci Am; 2000 Dec 15; 6(1):13-20. PubMed ID: 10696733
    [Abstract] [Full Text] [Related]

  • 9. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
    Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Castiel M, Nafa K, Offit K.
    N Engl J Med; 2002 May 23; 346(21):1609-15. PubMed ID: 12023992
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer.
    Hartmann LC, Schaid DJ, Woods JE, Crotty TP, Myers JL, Arnold PG, Petty PM, Sellers TA, Johnson JL, McDonnell SK, Frost MH, Jenkins RB.
    N Engl J Med; 1999 Jan 14; 340(2):77-84. PubMed ID: 9887158
    [Abstract] [Full Text] [Related]

  • 11. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.
    Metcalfe KA, Lubinski J, Ghadirian P, Lynch H, Kim-Sing C, Friedman E, Foulkes WD, Domchek S, Ainsworth P, Isaacs C, Tung N, Gronwald J, Cummings S, Wagner T, Manoukian S, Møller P, Weitzel J, Sun P, Narod SA, Hereditary Breast Cancer Clinical Study Group.
    J Clin Oncol; 2008 Mar 01; 26(7):1093-7. PubMed ID: 18195327
    [Abstract] [Full Text] [Related]

  • 12. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.
    Adem C, Reynolds C, Soderberg CL, Slezak JM, McDonnell SK, Sebo TJ, Schaid DJ, Myers JL, Sellers TA, Hartmann LC, Jenkins RB.
    Cancer; 2003 Jan 01; 97(1):1-11. PubMed ID: 12491499
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS.
    Oncologist; 1996 Jan 01; 1(5):326-330. PubMed ID: 10388011
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Prophylactic mastectomy for women with BRCA1 and BRCA2 mutations--facts and controversy.
    Eisen A, Weber BL.
    N Engl J Med; 2001 Jul 19; 345(3):207-8. PubMed ID: 11463017
    [No Abstract] [Full Text] [Related]

  • 19. Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation.
    Metcalfe KA, Foulkes WD, Kim-Sing C, Ainsworth P, Rosen B, Armel S, Poll A, Eisen A, Gilchrist D, Chudley A, Ghadirian P, Maugard C, Lemire EG, Sun P, Narod SA.
    Clin Genet; 2008 May 19; 73(5):474-9. PubMed ID: 18341607
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.